Related Experiment Videos
Vitamin K antagonist use in the elderly: special considerations
Virginie Siguret1, Eric Pautas, Isabelle Gouin-Thibault
1Hôpital Charles Foix (AP-HP), Laboratoire d'Hématologie, 7 Avenue de la République, 94205 Ivry-sur-Seine cedex, France. virginie.siguret@cfx.ap-hop-paris.fr
Future Cardiology
|October 7, 2009
Summary
Elderly patients over 75 increasingly use vitamin K antagonists (VKAs) for blood clots and atrial fibrillation. Careful VKA management and monitoring are key to minimizing bleeding risks in this population.
Area of Science:
- Geriatrics
- Pharmacology
- Cardiology
Background:
- The aging global population leads to a rise in elderly patients (75+) requiring anticoagulation.
- Vitamin K antagonists (VKAs) are crucial for treating venous thromboembolic disease and preventing embolism in nonvalvular atrial fibrillation.
- Despite proven benefits, VKA use remains suboptimal in this demographic.
Purpose of the Study:
- To review the specific management strategies for VKAs in elderly patients.
- To examine the associated hemorrhagic risks in this population.
- To provide insights for optimizing VKA therapy in older adults.
Main Methods:
- This review synthesizes current literature and clinical recommendations.
- Focuses on VKA management protocols for patients aged 75 and older.
- Analyzes factors contributing to hemorrhagic complications.
Main Results:
- Elderly patients present unique challenges in VKA management.
- Hemorrhagic risk is a significant concern in this frail population.
- Adherence to target international normalized ratio (2.0-3.0) is recommended.
Conclusions:
- Optimized VKA management, including patient education and diligent monitoring, is essential.
- These strategies can help mitigate bleeding risks in elderly patients on VKAs.
- Improving VKA utilization is critical for effective thromboembolic disease management in older adults.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...